Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Denmark-based healthcare company Novo Nordisk and Sciele Pharma, a developer of branded prescription products, have announced the availability of PrandiMet tablets, the first and only fixed-dose combination of the short-acting secretagogue repaglinide and insulin sensitizer metformin HCl for the treatment of type 2 diabetes in the US.
Subscribe to our email newsletter
PrandiMet is a meglitinide and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a meglitinide and metformin HCl or who have inadequate glycemic control on a meglitinide alone or metformin HCl alone.
PrandiMet targets three primary abnormalities of type 2 diabetes by stimulating the release of insulin from the pancreas, improving insulin sensitivity and decreasing gluconeogenesis. Insulin release is dependent on the presence of functioning beta cells in the pancreatic islets.
The combination of metformin and repaglinide has been shown to effectively reduce A1c levels. Although Prandin and metformin HCl have been used together for over 10 years, PrandiMet is the first treatment option which combines both into one pill, the two companies said.